• LinkedIn
  • Twitter
Vesigen Therapeutics
  • About
    • Company Overview
    • Team
    • Investors
  • Our Science
  • Programs
  • News
  • Careers
  • Contact
  • Menu Menu
  • About
    • Company Overview
    • Team
    • Investors
  • Our Science
  • Programs
  • News
  • Careers
  • Contact

Programs

Advancing a differentiated pipeline targeting diseases that cannot be addressed with conventional delivery technologies

Evaluating partnerships to combine our ARMM delivery technology with novel therapeutic modalities in order to develop more effective, next-generation medicines

Disease areas of focus

Vesigen is pursuing multiple programs through both in-house development and collaborations, currently focusing on the following disease areas:

Neurology

Delivery to the central nervous system, particularly into neurons, has proven extremely challenging for existing technologies. Vesigen is exploring ARMMs-based therapeutic programs targeting neurological diseases for which there are no available treatments.

Ocular

Current technologies for systemic and topical delivery of ophthalmologic therapies are inefficient and often limited by tolerability issues, and intravitreal injections are invasive and require direct physician involvement. Vesigen is developing therapeutic programs using ARMMs technology to overcome current limitations and improve options for patients.

Immune Modulation

Numerous validated intracellular targets in immunology remain undruggable and/or not accessible for gene editing, protein delivery, or RNA interference using existing drug delivery systems. Vesigen has demonstrated high-efficiency in vivo gene editing of this class of targets in difficult-to-reach cell types paving the way for safer and more efficacious therapeutic interventions.

Explore a partnership

Interested in partnering with Vesigen?

Contact Us

  • About
  • Our Science
  • Programs
  • News
  • Careers
  • Contact

Vesigen Therapeutics
790 Memorial Drive
Suite 103
Cambridge, MA 02139

LinkeInTwitter

© 2020 Vesigen Therapeutics
All rights reserved.
Privacy Policy
Terms of Use

Design and development by RainCastle Communications
Scroll to top
  • About
    • Company Overview
    • Team
    • Investors
  • Our Science
  • Programs
  • News
  • Careers
  • Contact